Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of [14C]-INCB086550
NCT05101369Phase 1Completed
- Sponsor
- Incyte
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of incb086550 in solid tumor, sponsored by Incyte. Primary endpoints: Total recovery of radioactivity from urine and feces at 2 weeks and Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion at 2 months. Started Jan 2022; status: completed.
02
Drugs
incb086550
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05101369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101369.